1. Home
  2. G vs GRFS Comparison

G vs GRFS Comparison

Compare G & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Genpact Limited

G

Genpact Limited

HOLD

Current Price

$34.21

Market Cap

5.8B

ML Signal

HOLD

Logo Grifols S.A.

GRFS

Grifols S.A.

HOLD

Current Price

$8.25

Market Cap

5.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
G
GRFS
Founded
1997
1940
Country
Bermuda
Spain
Employees
140000
25247
Industry
Professional Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.8B
5.5B
IPO Year
2007
N/A

Fundamental Metrics

Financial Performance
Metric
G
GRFS
Price
$34.21
$8.25
Analyst Decision
Buy
Hold
Analyst Count
6
2
Target Price
$49.50
$10.15
AVG Volume (30 Days)
2.5M
573.0K
Earning Date
05-07-2026
07-28-2022
Dividend Yield
2.21%
1.80%
EPS Growth
9.82
N/A
EPS
3.13
N/A
Revenue
$2,279,438,000.00
N/A
Revenue This Year
$9.20
$4.49
Revenue Next Year
$7.27
$6.42
P/E Ratio
$10.99
$18.67
Revenue Growth
N/A
N/A
52 Week Low
$33.14
$7.08
52 Week High
$50.24
$11.14

Technical Indicators

Market Signals
Indicator
G
GRFS
Relative Strength Index (RSI) 37.68 50.20
Support Level N/A $7.64
Resistance Level $38.03 $8.88
Average True Range (ATR) 1.08 0.19
MACD -0.04 -0.01
Stochastic Oscillator 22.05 39.06

Price Performance

Historical Comparison
G
GRFS

About G Genpact Limited

Genpact Ltd is an agentic, technology-solutions company offering digital transformation, data-driven operations, and technology-enabled services across multiple industries. Its core business services include decision support services; technology services like application lifecycle management, platform customization, and support, etc; and digital operations optimizing business processes. Genpact also offers data engineering, data management, and domain-based AI and generative AI solutions; develops new technology solutions for clients; and offers agentic solutions and technology consulting services. Its reportable segments are: High Tech and Manufacturing, which generate maximum revenue, Financial Services, and Consumer and Healthcare. Geographically, it derives maximum revenue from India.

About GRFS Grifols S.A.

Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.

Share on Social Networks: